Elevated PFAS Levels Linked to Higher Multiple Sclerosis Risk in Women, U.S. Study Finds

PFAS (per- and polyfluoroalkyl substances), or “forever chemicals,” are a large group of synthetic compounds widely used in consumer products and industrial applications for their water-, stain-, and grease-resistant properties.

They are extremely persistent in the environment and human body, leading to widespread contamination of drinking water sources.

In 2024, the EPA finalized the first federal National Primary Drinking Water Regulation (NPDWR) for six PFAS compounds, setting enforceable Maximum Contaminant Levels (MCLs).

• PFOA and PFOS: 4.0 parts per trillion (ppt) each (MCLG of 0, reflecting no safe level for cancer risk).
• PFHxS, PFNA, and HFPO-DA (GenX): 10 ppt each.
• Mixtures (of certain PFAS including PFBS): Hazard Index of 1.

As of 2026, the EPA has proposed retaining the strict limits for PFOA and PFOS while rescinding rules for the other four compounds and allowing utilities to request extensions for compliance until 2031 (originally 2029). Monitoring and public reporting requirements continue.

Many states have their own stricter or additional standards (e.g., Colorado, Washington, New York), filling gaps where federal rules are weaker.

PFAS contaminate public water systems and private wells nationwide:

• Recent EPA data (UCMR 5 and updates) indicate at least 176 million Americans drink water with detectable PFAS—potentially approaching 200 million.
• Hotspots include the Northeast, Southeast, West Coast, Great Lakes region, and areas near military bases (AFFF firefighting foam), industrial sites, airports, and wastewater facilities. States like NJ, CA, PA, OH, NY, and FL often show high detections.
• Globally, surface and groundwater studies show similar issues, with higher exceedances near known sources.

Testing (especially UCMR 5) underreports the full picture, as it covers larger systems and specific compounds; private wells and smaller systems are often untested.

PFAS exposure via drinking water is linked to immune effects, developmental issues, cancer risks (e.g., kidney), hormone disruption, and other concerns. The link to conditions like MS (as in the prior study) is an area of emerging research but not yet definitive for drinking water specifically.

Check your water:

Contact your utility for the latest Consumer Confidence Report or test results. Use tools like the EWG PFAS map or EPA resources. Private well owners should test directly.

Home filtration (most practical for individuals):

• Reverse osmosis (RO): Highly effective (often 90–99%+ removal) for PFAS and many other contaminants. Best for drinking/cooking water.
• Granular activated carbon (GAC) or carbon block: Good for long-chain PFAS (e.g., PFOA/PFOS); variable for short-chain. Look for NSF/ANSI 53 certification claiming PFAS reduction.
• Anion exchange: Effective but less common in homes.
• Avoid relying on standard pitchers without PFAS certification (e.g., some Brita models perform poorly).
• Boiling does not remove PFAS.

Replace filters on schedule—effectiveness drops otherwise. Certified systems (NSF/ANSI 53 or 58) are recommended. Point-of-use (kitchen tap) is usually sufficient and more affordable than whole-house.

Broader actions:

Support stronger regulations, proper disposal of PFAS-containing products, and source reduction. Utilities use GAC, anion exchange, or RO/nanofiltration for compliance.

PFAS contamination is a long-term challenge due to their persistence, but targeted filtration and ongoing regulatory/monitoring efforts can significantly reduce personal exposure. For location-specific advice, check local health departments or EPA resources.

The 2026 U.S. study (published in Environmental Research) provides intriguing but preliminary observational evidence linking certain PFAS to multiple sclerosis (MS), particularly in women.

It does not establish causation, and “thinking deeper” requires placing it in the broader context of MS etiology, PFAS science, exposure sources, and study limitations.

Researchers measured serum levels of PFHxS, PFOA, and PFOS in 439 participants (226 with MS) across two cohorts, comparing them to healthy controls and patients with similar neuroinflammatory diseases (NMOSD and MOGAD).

Key points:

• PFHxS showed the most consistent elevation in women with MS (stronger than in men, where associations were imprecise).
• Dose-response patterns: Higher levels correlated with increased MS odds (~53% overall per increase in PFHxS; highest vs. lowest quartiles >3.5x odds). PFOA showed weaker/similar patterns; PFOS was inconsistent.
• Disease specificity: Elevations were more pronounced vs. other autoimmune neurological conditions, suggesting possible MS-specific pathways (e.g., endocrine/steroid interactions or neuronal membrane effects, per exploratory analyses).

Multi-cohort design, comparison groups that help rule out general autoimmunity, adjustment for some factors, and near-ubiquitous PFAS detection (real-world relevance).

Deeper Limitations and Interpretation Challenges

• Association, not causation: Cross-sectional design means PFAS levels were measured after (or during) disease. Reverse causation is possible (e.g., MS-related metabolic/immune changes altering PFAS clearance or binding). No pre-diagnosis exposure data.
• Sex differences: Stronger in women, aligning with MS’s female bias (estrogen/immune interactions?), but mechanisms are speculative. Hormonal PFAS interactions were explored but preliminary.
• Confounding and generalizability: Small sample for subgroups; limited ethnic diversity; unmeasured factors (genetics like HLA, EBV exposure, vitamin D, smoking, BMI—known strong MS risks). PFAS often correlate with urban/lifestyle variables.
• Mixture reality: People are exposed to PFAS cocktails + other pollutants. This study focused on a few legacy compounds; real effects may involve interactions.

Exposure Sources and Relevance to Drinking Water

PFAS enter the body mainly via drinking water, food, dust, and consumer products. The study aligns with your earlier query on drinking water contamination:

• Ubiquitous low-level exposure (blood detection >99% in the study).
• Drinking water is a key modifiable source, especially near hotspots (military bases, industry). The 4 ppt MCL for PFOA/PFOS aims to reduce risk, though rollbacks/extensions complicate enforcement.
• Broader context: Everyday sources (stain-resistant fabrics, food packaging, firefighting foams) dominate for many people. Claims about specific emitters (e.g., wind turbines via fluoropolymers) are minor in comparison—polymeric PFAS in coatings erode minimally and contribute negligibly vs. total environmental load.

Reducing intake (filtered water, avoiding high-risk products) is practical regardless of MS status.

What “Thinking Deeper” Implies for Implications

Biological plausibility:

PFAS are immunotoxic and endocrine-disrupting. MS involves immune dysregulation attacking myelin. Links to other autoimmune conditions exist in literature, but specificity to MS needs mechanistic studies (e.g., transcriptomics mentioned here are tentative)

Public health angle:

If confirmed in longitudinal/multi-ethnic studies, it strengthens arguments for aggressive PFAS phase-outs and water treatment. However, overinterpreting risks could distract from proven MS factors (e.g., EBV vaccination research is promising).

Uncertainty and next steps:

Call for longitudinal cohorts tracking exposure before onset, better mixture analyses, and sex-stratified research. Dr. Hafler (Yale) noted in coverage: MS arises from gene-environment interplay—PFAS may be one environmental piece among many.

This study is a valuable signal warranting follow-up, not yet a definitive “link” for clinical advice.

For individuals with MS or concerns: Focus on evidence-based management, discuss exposures with your doctor, and prioritize tested risk reducers (vitamin D, smoking cessation, etc.).

Broader societal action on PFAS in water/products remains important.

Associations between perfluoroalkyl substances and multiple sclerosis in U.S. cohorts compared with NMOSD, MOGAD, and healthy controls

Here is a detailed breakdown of the study with the exact title: “Associations between perfluoroalkyl substances and multiple sclerosis in U.S. cohorts compared with NMOSD, MOGAD, and healthy controls.”

Authors: Farren B.S. Briggs et al. (multi-institutional, led by University of Miami).  Federico Montini ^b1, Charles F. Spurlock III ^cd, Christine Ryan ^e, Jessica N. Cooke Bailey ^f, Erika S. Trapl ^g, Guzel I. Shaginurova ^h, Lukasz S. Wylezinski ⁱ, Cheryl L. Sesler ^h, Mahboobeh Fereidan Esfahani ^j, Jessica Sagen ^b, Hannah E. Gardener ^k, Jacob L. McCauley ^l, Alberto J. Caban-Martinez ^a, Roberta Brambilla ^m, Lilyana Amezcua ⁿ, W. Oliver Tobin

Journal: Environmental Research, Volume 303, Part 1, 15 August 2026, Article 124763.

DOI: doi.org/10.1016/j.envres.2026.124763

Abstract Summary (Key Excerpts)

Recent European data suggested MS-PFAS associations may vary by sex. The researchers evaluated sex-stratified and disease-specific PFAS-MS associations in U.S. cohorts and explored endocrine and transcriptomic correlates.

Methods:

• Liquid chromatography-mass spectrometry quantified serum PFHxS, PFOA, and PFOS in 439 participants (226 MS, 106 healthy controls, 59 NMOSD, 48 MOGAD) across two U.S. cohorts.
• PFAS levels compared across groups with sex stratification.
• Exposure-risk models estimated MS odds.
• In MS-HC females: PFAS associations with sex-steroid metabolites; PFAS-correlated gene-expression in a subset.

Results:

• PFHxS consistently elevated in MS females vs. HC, NMOSD, and MOGAD females; PFOA similar but less uniform. Male associations imprecise.
• Dose-response and non-linear associations for PFHxS (primary in mixtures); directionally similar for PFOA. PFOS weaker.
• Exploratory: Significant MS × PFOA interactions for steroid metabolites; PFAS-correlated genes enriched in neuronal membrane pathways.

Conclusions:

• Consistent PFHxS (and lesser PFOA) association with MS, particularly in females.
• Suggests disease-specific (vs. general neuroinflammation) and sex-heterogeneous effects.
• Plausible pathways identified; calls for multi-ethnic longitudinal studies on temporality/causality.

Why This Study Matters

Controls for specificity:

Comparing to NMOSD/MOGAD (distinct antibody-mediated diseases with overlapping symptoms) strengthens evidence that the PFAS link may be more particular to MS pathology.

Sex focus:

Aligns with MS epidemiology (women affected ~3x more) and prior hints of sex differences in PFAS effects.

Mechanistic hints:

Endocrine disruption (steroid metabolites) and neuronal/synaptic gene changes could tie into demyelination or neuroimmune processes.

Full Context and Cautions

This is observational (cross-sectional). It shows higher PFAS in people with MS (especially women) but cannot prove PFAS caused or worsened the disease—disease processes might also affect PFAS levels. Effect sizes are moderate, and PFAS exposure is nearly universal, so individual risk contribution is small compared to genetics/EBV.

It builds on (and is consistent with) other recent work, such as Swedish studies on PFAS/PCBs and MS onset. Together, they highlight the need for prevention-focused research on environmental contributors.

Conclusions

Across two U.S. cohorts, PFHxS demonstrated consistent association with MS, particularly among females, while PFOA showed a similar but less uniform pattern. Exploratory findings suggest plausible pathways linking PFAS exposure to MS. Multi-ethnic and longitudinal studies are needed to expand generalizability and clarify temporality and causality.